Skip to main content
. 2023 Jul 13;110(10):1374–1380. doi: 10.1093/bjs/znad210

Fig. 1.

Fig. 1

Eligibility criteria in two randomized trials of neoadjuvant chemoradiotherapy in patients with (borderline) resectable pancreatic adenocarcinoma (pancreatic cancer)

*Chemotherapy, radiotherapy, immunotherapy. BRPC, borderline resectable pancreatic cancer; NCCN, National Comprehensive Cancer Network; PDAC, pancreatic ductal adenocarcinoma; RPC, resectable pancreatic cancer; DPCG, Dutch Pancreatic Cancer Group; LAPC, locally advanced pancreatic cancer.